Viral Clearance Market: Opportunities and Challenges

Viral Clearance Market: Opportunities and Challenges

The major players in the global viral clearance market are Wuxi Biologics (Cayman) (China), Merck KGaA (Germany), Charles River Laboratories International Inc. (US), Texcell Inc. (France), Kedrion (Italy), Vironova Biosafety (Sweden), Clean Cells (France), BSL BIOSERVICE Scientific Laboratories Munich GmbH (Germany), and ViruSure GmbH (Austria).
The rising R&D expenditure in pharmaceutical and biotechnology companies is a major factor driving the growth of the viral clearance market.

The global viral clearance market is expected to reach USD 0.72 billion by 2023 from an estimated USD 0.27 billion in 2018, at a CAGR of 21.7% during the forecast period.

Will pharmaceutical outsourcing further create opportunities for growth for players in the viral clearance market?

The rising R&D expenditure in pharmaceutical and biotechnology companies is a major factor driving the growth of the viral clearance market. According to Pharmaceutical Research and Manufacturers of America (PhRMA), the R&D expenditure of its member-companies increased to USD 71.4 billion in 2017 from USD 65.5 billion in 2016.

Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=62681197

In this scenario, the outsourcing of R&D and manufacturing processes has become increasingly prevalent and is now a major trend in the pharmaceutical industry. Many companies and institutes opt to outsource numerous core functions like manufacturing, clinical trial management, and portions of drug discovery to CROs, which provide services such as cell and virus bank characterization, genetic stability testing, raw material testing, and next-generation sequencing. Owing to technological advancements and the emergence of new technologies, it is not feasible for companies to undertake all testing functions in-house. On the other hand, CROs can afford to invest in extensive drug discovery infrastructure as they cater to multiple clients. By outsourcing various functions to CROs, pharmaceutical and biotechnology companies can reduce their operational costs and R&D budgets. Viral clearance studies constitute a major part of the services that are outsourced to CROs by the pharmaceutical and biotechnology companies. Hence, an increase in pharmaceutical outsourcing could potentially increase the growth opportunities for the viral clearance market.

How will the dearth of skilled professionals affect the viral clearance market?

The success of biological safety tests depends mainly on the expertise of the analysts themselves as much as the environmental conditions under which the test is performed. Skilled personnel with the relevant experience and knowledge are required in order to conduct viral clearance studies. Handling instruments used in viral safety testing also requires expertise. The dearth of skilled personnel is thus expected to restrain the growth of the viral clearance market to a certain extent.

Request Sample Report:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=62681197

According to an article in the Science in the City newsletter, Canada’s fast-growing biotech sector will face a shortage of 220,000 workers by 2020. Moreover, in India, there is an average of about four full-time researchers per 10,000 people in the labor force. This shortage of skilled labor is expected to affect the optimum growth potential of the viral clearance market in the coming years.

Browse Related Reports: 

Viral Inactivation Market by Product (Kits, Reagents, Systems, Services), Application (Stem Cell, Blood, Tissue, Cell & Gene Therapy), Method (Solvent Detergent, Pasteurization) & End User (Pharmaceutical and Biotechnology, CROs) – Global Forecast to 2021

Viral Vector Manufacturing Market by Type (Retrovirus, Gammaretrovirus, AAV), Disease (Cancer, Infectious Disease, Genetic Disorders), Application (Gene Therapy, Vaccinology), End User (Biotech companies, Research Institutes) – Global Forecast to 2023

About MarketsandMarkets™:

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the “Growth Engagement Model – GEM”. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write “Attack, avoid and defend” strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, “Knowledge Store” connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Media Contact
Company Name: MarketsandMarkets
Contact Person: Mr. Shelly Singh
Email: Send Email
Phone: 1-888-600-6441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/viral-clearance-market-62681197.html